Gland Pharma Q3 results: Net up 34% at Rs 273 cr
Revenue from operations rose to Rs 1,063 crore in the October-December period of the current fiscal as against Rs 859 crore in the same period of 2020-21 fiscal.21-01-2022
21-01-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Investor Presentation
Earnings Presentation on the Unaudited Financial Results for the Quarter and nine months ended December 31, 202121-01-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on the Unaudited Financial Results for the Quarter and nine months ended December 31, 202121-01-2022
Gland Pharma Ltd - 543245 - Board Meeting Outcome for Outcome Of The Board Meeting
The Board of Directors at its meeting held on January 21, 2022 has inter-alia approved the Unaudited financial results of the Company for the quarter and nine months ended December 31, 202121-01-2022
Gland Pharma Ltd - 543245 - Shareholding for the Period Ended December 31, 2021
Gland Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here13-01-2022
Gland Pharma Ltd - 543245 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- SAMPATH KUMAR PALLERLAMUDIDesignation :- Company Secretary and Compliance Officer07-01-2022
Gland Pharma Ltd - 543245 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nicomac Machinery Pvt Ltd06-01-2022
Gland Pharma Ltd - 543245 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Gland Celsus Bio Chemicals Pvt Ltd06-01-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Conference Call - Q3FY2203-01-2022
Gland Pharma Ltd - 543245 - Board Meeting Intimation for Quarterly Results
Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/01/2022 ,inter alia, to consider and approve the Unaudited financial results of the Company for the quarter and nine months ended December 31, 2021.28-12-2021